Literature DB >> 35288093

C1q+ macrophages: passengers or drivers of cancer progression.

Margot Revel1, Catherine Sautès-Fridman1, Wolf-Herman Fridman1, Lubka T Roumenina2.   

Abstract

The omics era made possible the quest for efficient markers for cancer progression and revealed that macrophage populations are much more complex than just the M1/M2 dichotomy. Complement C1q pops up as a marker of a tolerogenic and immunosuppressive macrophage populations in both healthy and tumor tissues, but the specific role of C1q+ tumor-associated macrophages (TAM) is poorly understood. C1q is co-expressed in healthy and tumor macrophages with human leukocyte antigen DR (HLA-DR), Apolipoprotein E (APOE), and mannose receptor C-type 1 (MRC1) (CD206), suggesting a resident origin of this population. TAM expressing C1q correlate with T cell exhaustion and poor prognosis in numerous cancers. Herein, we discuss the plural roles of C1q in these macrophages and how it could drive cancer progression.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C1q; T cell exhaustion; complement system; tumor-associated macrophages

Mesh:

Substances:

Year:  2022        PMID: 35288093     DOI: 10.1016/j.trecan.2022.02.006

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  3 in total

Review 1.  Inside-Out of Complement in Cancer.

Authors:  Martin Kolev; Madhumita Das; Monica Gerber; Scott Baver; Pascal Deschatelets; Maciej M Markiewski
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

2.  Prognostic and immune-related value of complement C1Q (C1QA, C1QB, and C1QC) in skin cutaneous melanoma.

Authors:  Huanglong Yang; Dehui Che; Yuxiang Gu; Dongsheng Cao
Journal:  Front Genet       Date:  2022-08-30       Impact factor: 4.772

3.  Autoantibodies against Complement Classical Pathway Components C1q, C1r, C1s and C1-Inh in Patients with Lupus Nephritis.

Authors:  Maria Radanova; Vasil Vasilev; Galya Mihaylova; Mariya Kosturkova; Uday Kishore; Lubka Roumenina
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.